**Curriculum Vitae**

Seth Eisenberg RN, ASN, OCN®, BMTCN™

1586 E Sunshine Cir

Saint George, UT 84790

253.709.5152

**Email:**

setheisenberg@comcast.net

**Website:**

[www.setheisenberg.net](http://www.setheisenberg.net)

Washington License: RN 00087046

Utah License: 12907556-3102

Current Position:

Oncology Nurse Consultant

Presentations:

Roundtable facilitator (1988) **“Bone Marrow Transplant Issues**,**”** ONS Congress, Denver, CO.

Roundtable facilitator (1988) **“Vascular Access,”** Seattle Bone Marrow Transplant Nursing Symposium, Seattle, WA.

Roundtable facilitator (1990) **“Use of humor in nursing inservices,”** ONS Congress, San Francisco, CA.

Abstract presentation (1990) **“Use of humor in nursing inservices,”** ONS Congress, San Francisco, CA.

Guest speaker (1993, 1994) **“Fluid and Medication Management for Marrow Transplant Patients,”** Quantum Healthcare, Seattle, WA.

Guest speaker (1993) **“Multi-channel Intravenous Infusion Devices in the Marrow Transplant Setting”** Abbott Laboratories, Research Triangle Park NC, Dallas TX.

National Teleconference participant(1994) **“Omniflow: Applications for infusion management therapy,”** Abbott Laboratories.

Poster presentation (1995) **“Bone Marrow Transplantation,”** Baylor “Big Picture” BMT Symposium, Dallas, TX.

Panel Presentation (1995) **“Managing Nausea, Vomiting, and Pain,”** Seattle Marrow Transplant Nursing Consortium, Seattle, WA.

Guest speaker and session coordinator (1996) “**Cardiac and pulmonary toxicities of high dose chemotherapy,”** ONS Fall Institute, Phoenix, AZ.

Guest speaker (2003 - 2015) “**SOS/VOD in HSCT Patients,”** Marrow and Stem Cell Transplant: Nursing Management in the First 100 Days, Seattle, WA.

Guest speaker (2006 - 2015) “**Mucositis in HSCT Patients,”** Marrow and Stem Cell Transplant: Nursing Management in the First 100 Days, Seattle, WA.

Guest speaker (2005) **“Chemotherapy Safety and Administration,”** University of Washington Foundations In Chemotherapy, Seattle, WA.

Guest Speaker (2005) **“Chemotherapy Safety Concerns: New Recommendations for an Old Problem,”** Contemporary Forums, Issues In Oncology, Seattle, WA.

Guest speaker (2005) **“The Clinical Burden of Oral Mucositis in Hematopoietic Stem Cell Transplantation,”** Portland, OR.

Podium and Poster presentation (2006) “**Therapeutic Administration of an Orange to Relieve the Taste and Smell Sensations Associated with Dimethyl Sulfoxide during Stem Cell Reinfusion**,” Seattle Nursing Research Consortium

Guest speaker (2006) **“The Clinical Burden of Oral Mucositis in Hematopoietic Stem Cell Transplantation,”** Denver, CO.

Guest speaker (2006) **“Focus on Hematologic Therapy/Oral Mucositis.”** Teleconference.

Guest speaker (2006) **“Chemotherapy Safety: What you don’t know can hurt you,”** Olympia, WA.

Speaker/Facilitator (2007) **ONS SIG Leadership Orientation Workshop** Las Vegas, NV

Guest speaker (2007) “**Sinusoidal Obstruction Syndrome,”** IBMTR Tandem BMT Symposium, Keystone, CO.

Guest speaker (2007) **“Anthracycline Extravasation Management,”** Las Vegas, NV, Reno NV.

Guest speaker (2008) **“Extravasation Management,”** Cincinnati OH, Boise ID, Phoenix AZ, Woodstock VT, Knoxville, TN; Anaheim, CA; Los Gatos, CA; Salt Lake City, UT; St. Joseph, MI.

Guest speaker (2008) **“Anthracycline Extravasation Management,”** Seattle, WA; Portland, OR; Indianapolis, IN.

Guest speaker (2008) Nursing research study: **“Relieving Taste and Smell Sensations Associated with Dimethyl Sulfoxide (DMSO) During Stem Cell Reinfusion: Establishing Evidence for a Traditional Nursing Intervention,”** Western Institute of Nursing Conference, Anaheim, CA.

Guest speaker (2008) **“Safe Handling and Administration of Chemotherapy,”** INS National Academy of Infusion Therapy, Phoenix, AZ.

Guest speaker (2008) **“Patient and Provider Safety with the Infusion Process,”** ONS Satellite Symposia, Philadelphia, PA.

Guest speaker (2008) **“Proper Handling of Hazardous Drugs: Topics for Oncology Nurses,”** Eugene, OR.

Guest speaker (2008) **“Chemotherapy Safety: The facts you should know,”** Portland, OR; Salt Lake City, UT; Dallas, TX.

Guest speaker (2008) **“HSCT Complications: HSOS—It’s not VOD any more,”** ONS Institute of Learning, Seattle, WA.

Guest speaker (2008-2009) **“Candida Infections—Where do we stand?”** Spokane, WA; Tacoma, WA; Tukwila, WA.

Guest speaker (2009) **“Vascular Access Hot Topics”**, IBMTR Tandem BMT Symposium, Tampa, FL.

Guest speaker (2009) **“Reducing the risk of nursing exposure to chemotherapy,”** Salt Lake City, UT; Phoenix, AZ; Sonoma, CA; Las Vegas, NV.

Guest speaker (2009) **“Nurse Safety with Hazardous Drugs: Where Do You Stand?**” San Antonio, TX.

Guest speaker (2009) Webinar: **“Safe Handling of Hazardous Drugs: Practical Considerations for Compounding and Administration.”**

Guest speaker (2009) “**Safe Handling of Hazardous Drugs: Practical Considerations for Compounding and Administration,”** APHON 33rd Annual Conference, Orlando, FL.

Guest speaker (2009) *“***Managing a Serious Complication of Oncological Treatment: Extravasation,”** Shoreline, WA (Infusion Nursing Society); Spokane, WA (ONS); St. Louis, MO, Tacoma, WA.

Guest speaker (2009) “**Reducing Exposure to Hazardous Drugs: What oncology nurses need to know,”** CANO 21st Annual Conference, Montreal, Quebec; Houston, TX; Lynwood, WA; Palm Springs, CA; MD Anderson 6th Annual Oncology Symposium, New York, NY; Huntsville Hospital University 2010 Oncology Conference Huntsville, AL; Indianapolis, IN.

Guest speaker (2009) **“Refractory Response to Platelet Transfusion Therapy,**” INS Fall National Academy of Infusion Therapy, Jacksonville, FL.

Panel Presentation (2009) **“Creating A Culture of Safety in Pharmacy,”** ASHP Midyear, Las Vegas, NV.

Guest speaker (2010) “**Managing a Serious Complication of Oncological Treatment: Extravasation,”** Portland, OR; Buffalo, NY; Tampa, FL; Honolulu, HI; Savannah, GA; Columbia, MO.

Guest speaker (2010) Webinar: **“Safe Handling of Hazardous Drugs In Healthcare.”**

Guest speaker (2010) “**Reducing Exposure to Hazardous Drugs: What all nurses need to know,”** Chicago, IL.

Guest speaker (2010) **“Safe Handling of Hazardous Drugs: An Overview for Oncology Nurses,”** 16th Annual ICCN Conference, Atlanta, GA.

Guest speaker (2010) **“Safe Handling of Hazardous Drugs: Risks and Practical Considerations,”** Satellite symposium, 35th Annual ONS Congress, San Diego, CA.

Guest speaker (2010) **“Platelet Refractoriness: It’s what’s in the bag,”** Puget Sound ONS, Seattle, WA

Television Panelist (KTCS Chanel 9 Video Presentation) (2010) **“Lifesaving Drugs; Deadly Consequences,”** an Investigate West Report, Seattle, WA.

Podium Presentation (2011) **“Prevention of DMSO-related Nausea and Vomiting by Prophylactic Administration of Ondansetron,”** IBMTR Tandem BMT Symposium, Honolulu, HI.

Guest speaker (2011) **“Hazardous Drugs: How Safe Is Your Practice?”** Boston, MA; Huntsville, AL; Los Angeles, CA.

Guest speaker (2011) **“Occupational Hazardous Drug Exposure: An Update,”** 36th Annual ONS Congress, Boston, MA.

Guest speaker (2011) **“Hazardous Drugs: A Hands-On Review of Safe Drug Administration,”** 36th Annual ONS Congress Breakfast Symposium, Boston, MA.

Guest speaker (2011) **“Closed System Transfer Devices: A Nursing Perspective,”** Taiwan Society of Hospital Pharmacists, China Medical University, Taichung, Taiwan.

Guest speaker (2011) **“Hazardous Drugs: Minimizing Risks/Maximizing Safety,”** Taipei, Taiwan.

Guest speaker (2011) **“Implementation of the NIOSH Hazardous Drug Guidelines: The US Experience,”** Taipei, Taiwan.

Guest speaker (2011) **“Out of the vein or out of the bag: Vascular access and safe handling issues in oncology patients,”** MAVANS, Boston, MA.

Guest speaker (2011) **“Biologic Therapy,”** INS National Academy of Infusion Therapy, Los Angeles, CA.

Guest speaker (2011) **“Hazardous Drugs: Is your practice putting patients and providers at risk?**” ASHP Midyear, New Orleans, LA.

Guest speaker (2012) **“Hazardous Drugs: How Safe Is Your Practice?”** Lexington, KY.

Guest speaker (2012) “**Hazardous Drug Update: Accountability Comes to Washington State”** Puget Sound ONS Annual Symposia, Lynwood, WA.

Guest speaker (2012) **“Out of the vein or out of the bag: Vascular access and safe handling issues in oncology patients,”** New Hampshire Vascular Access Nursing Society Manchester, NH; Maine Vascular Access Nursing Society, Portland, ME.

Guest speaker (2012) “**Hazardous Drugs: What you need to know to practice safely: a pediatric perspective,”** International Congress of Pediatric Oncology and Hematology, Cancun, Mexico.

Guest speaker (2012) **“Chemotherapy Extravasation: Nursing Perspectives,”** International Congress of Pediatric Oncology and Hematology, Cancun, Mexico.

Guest speaker (2012) **“Hazardous Drugs: What You Need to Know to Practice Safely: the US Experience,”** Prague, Czech Republic.

Guest speaker (2012) **“Hazardous Drugs: What You Need to Know to Practice Safely,”** Nashville, TN.

Guest speaker (2012) **“The Hidden Dangers of Hazardous Drugs,”** Dallas TX INS Chapter.

Guest speaker (2013) Webinar: **“Hazardous Drug Safety: LEANing the way from pharmacy to nursing to patient,”** Veterans Health Administration (VHA).

Guest speaker (2013) **“Biotherapy,”** NHIA Annual Conference, Dallas, TX.

Guest speaker (2013) **“The Hazardous Drug Problem,”** Washington DC, APHON Chapter

Guest speaker (2013) **“Patient Clinical Outcomes and Survival in Relapsed Multiple Myeloma,”** Richland, WA; Poulsbo, WA; Mt. Vernon, WA.

Guest speaker (2013) **“Patient Clinical Outcomes and Survival in Previously Untreated Multiple Myeloma,”** Seattle, WA; Sedro Woolley, WA; Denver, CO; Boise, ID.

Guest speaker (2013) **“Hazardous Drug Management Workshop: Implementation Strategies for Safety—from Pharmacy to Nursing,”** Greater New York Hospital Association, New York, NY.

Guest speaker (2013) **“Platelet Refractoriness,”** INS National Academy of Infusion Therapy, Boston, MA.

Guest speaker (2014) **“Protecting Yourself From Hazardous Drugs,”** ONS Chapter, Cleveland, OH; Minneapolis, MN.

Guest speaker (2014) **“Extravasation and Hazardous Drug Safety Issues,”** INS Rocky Mountain Chapter, Denver, CO.

Guest speaker (2014) **“Establishing A Plan For Length of Therapy in Multiple Myeloma,”** Bow, WA; Richland, WA; Walla Walla, WA; Seattle, WA; Edmonds, WA

Guest speaker (2014) **“Hypersensitivity: Infusion Reaction Management,”** 39th Annual ONS Congress, Anaheim, CA.

Guest speaker (2014) **“The Hidden Dangers of Hazardous Drugs,”** Orange County ONS Chapter, Newport, CA.

Guest speaker (2014) Webinar: **“Drug Hypersensitivity Reactions: Mechanisms and Management.”**

Guest speaker (2014) **“Velcade: Evolving treatment for mantle cell lymphoma and multiple myeloma,”** Woodlands, TX.

Guest speaker (2014) Webinar: **“Infusion Pumps: The Delivery Mechanism For Your Compounded Products.”**

Guest speaker (2014) **“Establishing A Plan For Length of Therapy in Multiple Myeloma,”** Montgomery, TX.

Guest speaker (2014) **“The Hidden Dangers of Hazardous Drugs,”** AVA Chapter, Albuquerque, NM.

Guest speaker (2014) **“Point of Care: IV Fluid Transfer: Infection Management & Hazardous Drug Handling,”** Ann Arbor, MI; Duluth, MN; Villages, FL; Sacramento, CA.

Guest speaker (2014) **“The Hidden Dangers of Hazardous Drugs,”** INS Chapter, Baltimore, MD.

Guest speaker (2015) **“Establishing A Plan For Length of Therapy in Multiple Myeloma,”** Spring, TX.

Guest speaker (2015) **“Building Solidarity Between Departments: Nursing Implications of USP<800>,”** Greater New York Hospital Association, New York, NY.

Guest speaker (2015) **“Hazardous Drugs And Multidisciplinary Risk Reduction Strategies,”** Southeast Society of Health System Pharmacists, Pembroke Pines, FL.

Guest speaker (2015) **“The Hidden Dangers of Hazardous Drugs,”** INS Chapter, Hollywood, FL; INS Chapter, Chicago, IL; ONS Symposium, Portland, OR; INS Chapter Chicago, IL

Guest speaker (2015) **“Point of Care: IV Fluid Transfer: Infection Management & Hazardous Drug Handling,”** INS Chapter, Charlotte, NC.

Guest speaker (2015) Webinar: **“The Hidden Dangers of Hazardous Drugs,”** ProCE.

Guest speaker (2015) **“Hazardous Drug Safety: Minimizing Your Vulnerabilities,”** ONS Chapter, Stuart, FL.

Guest speaker (2015) **“Hazardous Drug Safety,”** Guadalajara, MX; Monterrey, MX; Mexico City, MX.

Guest speaker (2016) **“The Hidden Dangers of Hazardous Drugs,”** ONS Chapter, Virginia Beach, VA; INS Chapter, Tulsa OK.

Guest speaker (2016) **“Oral Treatment for Patients With Multiple Myeloma,”** Mt. Vernon, WA.

Moderator (2016) ONS National Twitter Chat on Safe Handling **“Spotlightonsafety#”**

Guest speaker (2016) **“Self-advocating For Protection Against Hazardous Drugs,”** 41st ONS Congress, San Antonio, TX.

Guest speaker (2016) **“Nursing Implications of USP<800>”,** Miami, FL.

Guest speaker (2016) **“Self-Advocating For Protection Against Hazardous Drugs Update,”** ONS Updates in Oncology, Minneapolis, MN.

Guest speaker (2016) “**Self-Advocating For Protection Against Hazardous Drugs: USP<800>,”** MOASC Conference, Anaheim, CA.

Guest speaker (2016-2017) “**GAZYVA® (obinutuzumab) for first-line Chronic Lymphocytic Leukemia (CLL) and R/R Follicular Lymphoma”,** Chico, CA; Reno, NV; Oakland, CA**.**

Guest speaker (2017) **“Ninlaro: An Oral Treatment Option,”** Mt. Vernon, WA.

Guest speaker (2017) **“Nursing Implications of USP<800>”,** Washington, DC.

Guest speaker (2017) **“Ready for <USP 800> The Next Chapter in Hazardous Drug Safety”,** 42nd Annual ONS Congress, Denver, CO.

Guest speaker (2017) **“Paying Attention To The Details: Strategies To Promote Hazardous Drug Safety,”** INS National Academy, Minneapolis, MN.

Guest speaker (2017) Webinar: **“Changes in Pharma Regulations: How it Affects the OR Nurse,”** ASORN.

Guest speaker (2017) **“Overview of Rituxan Hycela,”** Seattle, WA; Tacoma, WA; Auburn, CA; El Paso, TX; Honolulu HI; Bellevue, WA; Roseville, CA; Spokane, WA; Colorado Springs, CO; Houston, TX; Anchorage, AK.

Guest speaker (2017) Webinar: **“Hazardous Drugs and USP <800>,** BD.

Guest speaker (2017) **“Personal Protective Equipment and Closed System Transfer Devices,”** INS Fall Conference, Atlanta, GA.

Guest speaker (2017) **“Hazardous Drugs and USP <800>,”** California Central Valley ONS, Fresno, CA.

Guest speaker (2017) **“Preparing for USP <800>,”** Nevada Cancer Control Summit, Reno, NV.

Guest speaker (2017) **“Surprising Facts About USP <800> Readiness: What You Need to Know Today to be in Compliance Tomorrow,”** ASHP Midyear, Orlando, FL.

Guest speaker (2018) **“USP <800> and Safe Handling of Chemo/Bio/Immunotherapy,”** Practical Applications of New Agents in Oncology, San Antonio, TX.

Guest speaker (2018) **“Preparing for USP <800>,”** PSONS 40th Annual Nursing Symposium, Lynnwood, WA.

Poster Presentation (2018) **“The Role of Low-Volume IV Tubing for Outpatient Infusions and Clinical Research,”** 40th Annual ONS Congress, Washington DC.

Guest speaker (2018) **“Safe Hazardous Drug Handling: USP <800> and Best Practices,”** AVAHO, Chicago, IL.

Guest speaker (2018) “**Hazardous Drug Safety for The Non-Oncology Nurse,”** Update in Medical-Surgical Nursing 16th Annual Conference, Seattle, WA.

Guest speaker (2018) **“Hazardous Drug Safety and USP <800>,”** Hood River, OR.

Poster Presentation (2019) **“Development of A Free Website for Safe Handling of Hazardous Drug Excreta,”** 41st Annual PSONS Symposium, Renton, WA.

Guest speaker (2018-2019) **“Gazyva for Previously Untreated Follicular Lymphoma”,** Renton, WA.

Guest speaker (2019) **“Countdown to USP <800>”,** 44th Annual ONS Congress, Anaheim, CA.

Guest speaker (2019) **“Considerations for Tailoring First-line Follicular Lymphoma Treatment,”** Portland, OR; Salem, OR; Redding, CA; Salt Lake City, UT; Issaquah, WA; Reno, NV; Coos Bay, OR.

Poster Presentation (2019) **“Development of A Free Website for Safe Handling of Hazardous Drug Excreta,”** 44th Annual ONS Congress, Anaheim, CA.

Guest speaker (2019) **“Hazardous Drug Safety Essentials,”** Philadelphia, PA.

Guest speaker (2019) **“Hazardous Drugs in Non-Oncology Patients,**” 43rd AACN Symposium, Lynnwood, WA.

Guest Speaker (2019) “**Nursing Perspectives on USP <800>”,** 2019 New Mexico Society of Hospital Pharmacists, Albuquerque, NM.

Guest Speaker (2019) **“Hazardous Drug Safety for Oncology Nurses,”** Northern New Jersey ONS Symposium, Mahwah, NJ.

Guest Speaker (2019) **“Hazardous Drug Safety for Nurses,”** Northwestern Hospital Grand Rounds, Chicago, IL.

Guest Speaker (2019) **“Hazardous Drugs and <USP> 800,”** Michigan Traverse Bay Region ONS, Traverse Bay, MI; Metropolitan Detroit ONS, Detroit, MI.

Podcast (2019) “**Episode 77: A Turning Point for Safe Handling Practice**,” Oncology Nursing Society. <https://www.ons.org/podcasts/episode-77-turning-point-safe-handling-practice>.

Podcast (2019) **“What you need to know about hazardous drugs,”** <https://open.spotify.com/episode/5kCV3ssJ5z6r5cl04OubJg>.

Guest Speaker (2020) **“Hazardous Drug Safety: Answering some of the difficult questions,”** ONS Bridge e-Conference.

Guest Speaker (2020) **“Safe Handling of Hazardous Drugs in Home Infusion Therapy,”** INS 2020 Conference.

Guest Speaker (2021) **“Subcutaneous Chemotherapy and Biotherapy: The evolution of an old route,”** PSONS Virtual Presentation.

Podcast (2021) **“Episode 51**: **Administer Rituximab immunotherapy with confidence,”** Oncology Nursing Society. <https://podcasts.google.com/feed/aHR0cHM6Ly9vbnN2b2ljZS5saWJzeW4uY29tL3Jzcw/episode/NjZjZjM2MDMtNGIyNS00MjhjLThlYTctYWJlNTMyN2ZiN2E0?ep=14>

Guest Speaker (2021) Webinar: **“Optimizing Safety of Oncology Infusion Therapy.”**

Guest Speaker (2021) “**Finding Your Passion: Gaining inspiration and inspiring others,”** 42nd Annual PSONS Symposium, Lynnwood, WA.

Guest Speaker (2021) “**Finding Your Passion: Gaining inspiration and inspiring others,”** PSONS Virtual Presentation.

Guest Speaker (2021) “**Innovation in Cancer Care IV Therapy: Maximizing safety and Efficiency with Smart Pumps and Closed System Transfer Devices**,” 5th Asian Oncology Nursing Society Conference Virtual Presentation.

Guest Speaker (2022): **“Protecting Clinicians from Hazardous Drug Exposures,”** Infusion Nursing Society Webinar.

Poster Presentation (2022): **“Sequential Hazardous Drug Wipe Testing in an Ambulatory Cancer Center,”** 47th Annual ONS Congress, Anaheim, CA.

Poster Presentation (2022): **“Measuring Aerosols Generated by Toilet Flushing, and Evaluating Effectiveness of Splashblocker®”,** 47th Annual ONS Congress, Anaheim, CA.

Guest Speaker (2022) Webinar: **“Meet USP <800> Requirements for CSTD Utilization,”** Pharmacy Purchasing and Products *To The Point Series.*

Publications and Educational Media:

Ford, R., & Eisenberg, S. (1988-1990). Eds. Bone Marrow Transplant Nursing Newsletter (BMT SIG).

Ford, R., & Eisenberg, S. (1990). **Bone marrow transplant. Recent advances and nursing implications.** In Christine Miaskowski (Ed.) *Nursing Clinics of North America,* 25(2).

Eisenberg, S., & Maracich, L. (1992).Bone Marrow Transplant Standards of Care.

Eisenberg, S. (1993). **Multi-Channel Medication Management System Simplifies Drug Delivery to BMT Patients**. *Infusion Management Update*.

Eisenberg, S. (1991). **Should continuous intravenous (I.V.) heparin be infused via a Y site?** *Critical Care Nurse*. 19(3).

Eisenberg, S. (1997). **Intravenous Drug Compatibility: A challenge for the Oncology Nurse**. *ONS Forum* June.

Eisenberg, S. & Dougan, C. (2003-2006). Eds. **Chemotherapy SIG Newsletter**, <http://chemotherapy.vc.ons.org/page/152147/index.v3page;jsessionid=49mcmnto2mrr9>

NIH **Chemotherapy and You** (2006). Content Reviewer.

Krames Media **Chemotherapy** Patient Educational booklet (2006). Content Reviewer.

ONS**Chemotherapy and Biotherapy Guidelines** (2007) Chapter II Content Contributor, *ONS Press*.

Eisenberg, S. (2008). **Sinusoidal Obstruction Syndrome in Hematopoietic Stem Cell Transplant Patients.** *ONS Forum* 35(3).

Eisenberg, S. (2008). **Safe handling and administration of Hazardous Drugs**. *Journal of Infusion Nursing*. (January).

(2008-2013). ONS Connect Contributing Editor

Eisenberg, S. (2010). **Refractory Response to Platelet Therapy**. *Journal of Infusion Nursing*, Volume 33(2).

**Safe Handling of Hazardous Drugs** (Web course) (2010). Content Contributor.

**Lifesaving Drugs, Deadly Consequences** (print/video) (2010) Content Contributor <http://invw.org/2010/07/09/chemo-main/>

Potter, P., Eisenberg, S., Cain, K., & Berry, D. (2011). **Orange Interventions for Symptoms Associated With Dimethyl Sulfoxide During Stem Cell Reinfusions**. *Cancer Nursing,* (34(5).

Eisenberg, S. (2011). Safe Handling of Hazardous Drugs, 2nd Edition. Content Contributor, *ONS Press*.

Eisenberg, S. (2011). **Systemic Therapy for Breast Cancer**, in *Breast Cancer*, ONS Site Specific Series, *ONS Press*.

Eisenberg, S. (2011). **Accessing implanted ports: still a source of controversy.** *Clinical Journal of Oncology Nursing*, June.

Krames Media Oncology, Symptoms Patient Educational materials (2011). Content Reviewer.

Eisenberg, S. (2012). T**he NIOSH Safe Handling of Hazardous Drugs Guidelines Becomes State Law.** *Journal of Infusion Nursing.* Sept/Oct*.*

Eisenberg, S. (2012). **Biologic Therapy**. *Journal of Infusion Nursing.* Sept/Oct*.*

Eisenberg, S. (2012). **Collaboration for Managing Hazardous Drugs**. *Pharmacy Purchasing & Products,* October.

Eisenberg, S. (2012). **Infusion Reactions** (Chapter 6), in M. Kaplan (Ed.) *Oncologic Emergencies*, 2nd Edition, *ONS Press*.

Eisenberg, S. (2013). **Prevention of Dimethylsulfoxide-Related Nausea and vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells**. *Oncology Nursing Forum,* May, 40(3).

Krames Media Oncology. Symptoms Patient Educational materials. (2013, 2016). Content Reviewer.

Berry, D., Cunningham, T., Eisenberg, S., Wickline, M, Hammer, M. & Berg, C. (2014) **Improving Patient Knowledge of Discharge Medications in an Oncology Setting**. *Clinical Journal of Oncology Nursing*, February, 18(1):35-7.

Eisenberg, S. (2014). **Ensure Nursing Safety During Hazardous Drug Administration**. *Pharmacy Purchasing & Products,* April.

ONS Core Curriculum for Oncology Nursing (2014). Review Editor, *Elsevier*.

Eisenberg, S. (2015). **Hazardous Drug Handling In Light Of USP<800>**. *Pharmacy Purchasing & Products,* May.

Eisenberg, S. (2015). **Infusion Reaction** (Case 12), in M. Polovich and M. Garzo Saria (Eds.) *Chemotherapy and Biotherapy Case Studies*. ONS Press.

Eisenberg, S. (2016). **Reducing Exposure to Occupational Drugs. Q&A**. *Pharmacy Purchasing & Products,* February.

Dorcy-Shannon, K., Elgar, S., Heye, D., Ford, R., Bohl, S., Eisenberg, S. et al. **From Student to Practicing Oncology Nurse: A Novel Collaboration to Create a Transition to Practice Program in Ambulatory Cancer Care.** *Clinical Journal of Oncology Nursing,* 20(3).

Eisenberg, S. (2016). **What Are The Factors For Choosing a CSTD?** *Pharmacy Purchasing & Products,* February Oncology Supplement.

Eisenberg, S. (2016). **A Call To Action For Hazardous Drug Safety: Where we have been and where we are now.** *Clinical Journal of Oncology Nursing,* 20(4).

Krames Media Oncology. Symptoms Patient Educational materials (2016). Content Reviewer.

Eisenberg, S., and Massoomi, F. (2016). **Closed System Transfer Devices: An Introduction.** In Joint Commission Resources “Improving Safe Handling Practices for Hazardous Drugs.” *JCR Publications.*

Ready4 800 (2017). Educational Videos. Presenter and content contributor.

Eisenberg, S. (2017). **Safe Handling of Hazardous Drugs**, 3rd Edition. Content Contributor.

Eisenberg, S. (2017). **Working with nursing to ensure USP<800> compliance.** (Q&A). *Pharmacy Purchasing & Products,* February.

Eisenberg, S. (2017). **Hazardous Drugs and USP<800>: Implications for Nurses**. *Clinical Journal of Oncology Nursing*. 21(2).

Walton, AM., Eisenberg, S., and Friese, C. (2017). **Hazardous Drugs: Legislative and regulatory efforts to improve safe handling**. *Clinical Journal of Oncology Nursing, 21(2).*

Eisenberg, S. (2018). **USP <800> and Strategies to Promote Hazardous Drug Safety.** *Journal of Infusion Nursing.* Jan/Feb, (41).

Eisenberg, S. & Pacheco, L. (2018). **Applying Hazardous Drug Standards to Antineoplastics Used for Ophthalmology Surgery**. *AORN Journal*, Feb.

Eisenberg, S. (2018). **Infusion Reactions, Extravasation, and Transfusion Reactions** (Chapter 7), in M. Kaplan (Ed.) *Oncologic Emergencies*, 3rd Edition, *ONS Press*.

Eisenberg, S. (2018). **SOPs for USP <800>: A Nursing Perspective.** *PPPmag.com,* December 2018 S1.

Eisenberg, S. (2019). **Handle with care: How USP <800> will affect nursing practice**. In Pirschel, C., *ONS Voice, September.*

Kidd, S., Christiansen, K., Coumar, A., Williams, J., Ito, K., Petersen, A., Niculescu, R., Eisenberg, S., Schwab, D., Wojnar, D., Jablonski, A., & Shannon Dorcy, K. (2020). **A Dedicated Education Unit and a Novel Resident Nurse Transition-to-Practice Program in an Ambulatory Oncology Setting.** *Seminars in Oncology Nursing, May.*

Van Gerpen, R. & Eisenberg, S. (2020). **When function becomes malfunction: How to approach medical device failures.** *ONS Voice, June.*

Walton, A., Eisenberg, S., & Olsen, M. (2020). **Protect Staff with CSTDs**. *Pharmacy Purchasing and Products, March.*

Eisenberg, S. (2020). **Hepatorenal and Bladder Complications** (Chapter 10). In *Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice, 3rd Ed., ONS Press*.

Schmit-Pokorny, K. & Eisenberg, S. Eds (2020). **Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice,** 3rd Ed., ONS Press.

Massoomi, F., Eisenberg, S., & Jorgenson, J. (2021). **Lean Thinking for CSTDs**. *Pharmacy Practice News,* March.

Eisenberg, S., Ito, K., & Rodriguez, A. (2021). **Hazardous Drug Contamination. Presence of bathroom contamination in an ambulatory cancer center**. *Clinical Journal of Oncology Nursing,* 25(2).

Eisenberg, S., Klein, C. (2021). **Safe Handling of Hazardous Drugs in Home Infusion**. *Journal of Infusion Nursing,* 44(3).

Eisenberg, S. (2021). **Subcutaneous Administration: Evolution, challenges, and the role of hyaluronidase.** *Clinical Journal of Oncology Nursing,* 25(6).

Eisenberg, S. (2022). **Closed safety system for administration (CSSA): Proposal for a new cytotoxic chemotherapy acronym.** *British Journal of Nursing,* 31(10) Oncology Supplement

Nursing Research

**Principal Investigator:** Therapeutic Administration of Orange for the relief of DMSO-related symptoms.

**Principal Investigator:** Prevention of DMSO-Related Nausea And Vomiting By Prophylactic Administration Of Ondansetron For Patients Receiving Cryopreserved Hematopoietic Stem Cells

Nursing Awards

2017 March of Dimes Nurse of the Year for the Advancement of Research

2018 ONS Susan Baird Excellence In Clinical Writing Award

2021 ONS Distinguished Award for Consistent Contribution to Nursing Literature

Professional Organizations and Roles:

Member: Oncology Nursing Society since 1983

Vice President Greater Las Vegas Chapter ONS (1984-1986)

Member: ONS Bone Marrow Transplant Special Interest Group (SIG)

Member: ONS Chemotherapy Special Interest Group (SIG)

Member: Intermountain Chapter, Oncology Nursing Society

Member: Washington State Department of Labor and Industries Hazardous Drug Working Committee (2012-2022)

Member ONCC Bone Marrow Transplant Role Delineation Study Committee (2011)

Member ONCC Bone Marrow Transplant Test Development Committee and Item Writer Mentor (2013-2018)

Member: ONCC Bone Marrow Transplant Test Development Committee Chairperson (2013-2015)

Member ONS Nominating Committee (2022-2023)

Member: ASTM, participant in F23 chemotherapy gown permeation standard development

ONS Chemotherapy SIG Newsletter Editor (2003-2006)

ONS Chemotherapy SIG Coordinator (2006-2008)

ONCC OCN® Test Writer (2006, 2007)

ONCC OCN® Test Development Committee (2006 - 2011)

ONS SIG Leadership Orientation Workshop Coordinator (2007)

ONS SIG Council Chair (2008-2009

ONS Connect Contributing Editor (2008-2012)

Education

California State University Northridge

University of Nevada Las Vegas